Alexandria Venture Investments was among the participants in a series B round for Wugen, which is developing cellular therapeutics for cancer.
US-based oncology therapy developer Wugen closed a $172m series B round featuring Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, yesterday.
Abingworth and Tybourne Capital Management co-led the round, which included investment and financial services group Fidelity, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Velosity Capital, Falcon Edge Capital, RiverVest Venture Partners, Lyzz Capital and Lightchain Capital.
Wugen is developing a pipeline of chimeric antigen receptor (CAR) T-cell and…
